Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3
AM Lesokhin; B Arnulf; R Niesvizky; M Mohty; NJ Bahlis; MH Tomasson; P Rodrguez-Otero; H Quach; NS Raje; S Iida; M Raab; A Czibere; S Sullivan; E Leip; A Viqueira; V Blunk; X Leleu;
Hematol Transfus Cell Ther. 2022;44 Supl 2:S245-6
INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2
H Einsele; S Parekh; D Madduri; B Santomasso; JG Pérez-Larraya; NWV Donk; B Arnulf; M Mateos; KC Braganca; H Varsos; MJ Carrasco-Alfonso; M Akram; N Lendvai; CC Jackson; Y Olyslager; E Zudaire; C Li; D Geng; A Jakubowiak; A Cohen;
Hematol Transfus Cell Ther. 2021;43 Supl 1:S263-4
UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN¿DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
SZ Usmani; JG Berdeja; A Jakubowiak; M Agha; AD Cohen; D Madduri; P Hari; T Yeh; Y Olyslager; A Banerjee; CC Jackson; A Allred; E Zudaire; W Deraedt; X Wu; L Pacaud; M Akram; Y Lin; T Martin; S Jagannath;
Hematol Transfus Cell Ther. 2021;43 Supl 1:S272